Versant Capital Management Inc Has $52,000 Stock Holdings in Envista Holdings Co. (NYSE:NVST)

Versant Capital Management Inc boosted its holdings in shares of Envista Holdings Co. (NYSE:NVST) by 1,420.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 3,147 shares of the company’s stock after acquiring an additional 2,940 shares during the period. Versant Capital Management Inc’s holdings in Envista were worth $52,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Envista by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 17,167,767 shares of the company’s stock worth $413,056,000 after acquiring an additional 944,596 shares during the period. Ariel Investments LLC boosted its position in shares of Envista by 25.3% during the first quarter. Ariel Investments LLC now owns 8,892,200 shares of the company’s stock worth $190,115,000 after purchasing an additional 1,795,258 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Envista by 65.3% during the fourth quarter. Franklin Resources Inc. now owns 5,262,092 shares of the company’s stock worth $126,606,000 after purchasing an additional 2,077,786 shares in the last quarter. Nuance Investments LLC boosted its position in shares of Envista by 21.6% during the first quarter. Nuance Investments LLC now owns 4,781,320 shares of the company’s stock worth $102,224,000 after purchasing an additional 850,266 shares in the last quarter. Finally, Swedbank AB bought a new position in shares of Envista during the first quarter worth $53,412,000.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on NVST. JPMorgan Chase & Co. reduced their price target on shares of Envista from $29.00 to $23.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. Needham & Company LLC reissued a “hold” rating on shares of Envista in a research report on Tuesday, July 16th. Robert W. Baird cut their price objective on shares of Envista from $19.00 to $17.00 and set a “neutral” rating on the stock in a research report on Monday, July 22nd. Piper Sandler cut their price objective on shares of Envista from $18.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 30th. Finally, Evercore ISI cut their price objective on shares of Envista from $24.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 25th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $19.95.

Envista Stock Down 0.1 %

NYSE:NVST traded down $0.01 on Tuesday, hitting $15.76. 2,999,620 shares of the company’s stock were exchanged, compared to its average volume of 2,377,213. The firm has a 50-day moving average price of $17.04 and a 200-day moving average price of $19.65. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.27 and a quick ratio of 1.93. Envista Holdings Co. has a 52 week low of $15.66 and a 52 week high of $35.60. The company has a market cap of $2.71 billion, a P/E ratio of -22.15, a price-to-earnings-growth ratio of 14.74 and a beta of 1.31.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.